SKYE vs. MDWD, RZLT, CRDF, IVA, FULC, BTMD, SOPH, GOSS, ANNX, and HURA
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include MediWound (MDWD), Rezolute (RZLT), Cardiff Oncology (CRDF), Inventiva (IVA), Fulcrum Therapeutics (FULC), biote (BTMD), SOPHiA GENETICS (SOPH), Gossamer Bio (GOSS), Annexon (ANNX), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.
Skye Bioscience vs.
MediWound (NASDAQ:MDWD) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Skye Bioscience has a net margin of 0.00% compared to MediWound's net margin of -142.29%. Skye Bioscience's return on equity of -45.78% beat MediWound's return on equity.
MediWound has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500.
In the previous week, Skye Bioscience had 8 more articles in the media than MediWound. MarketBeat recorded 10 mentions for Skye Bioscience and 2 mentions for MediWound. Skye Bioscience's average media sentiment score of 1.01 beat MediWound's score of 0.34 indicating that Skye Bioscience is being referred to more favorably in the news media.
MediWound has higher revenue and earnings than Skye Bioscience. MediWound is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
MediWound presently has a consensus price target of $31.33, suggesting a potential upside of 74.36%. Skye Bioscience has a consensus price target of $16.60, suggesting a potential upside of 865.12%. Given Skye Bioscience's higher possible upside, analysts plainly believe Skye Bioscience is more favorable than MediWound.
MediWound received 383 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 62.23% of users gave MediWound an outperform vote.
46.8% of MediWound shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Skye Bioscience beats MediWound on 10 of the 16 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:SKYE) was last updated on 4/23/2025 by MarketBeat.com Staff
Buy SKYE Stock Free SKYE Stock Alerts